Thought Leader

Mission of the MASLD Community

Dedicated to fostering collaboration, driving innovation, and improving outcomes for patients living with Metabolic Associated Steatotic Liver Disease.

Engage with MASLD/MASH Experts in Your Region

Connect with regional specialists for personalized guidance, professional training, and continuous support in MASLD/MASH.

Expert Insights

Benefit from expert-driven resources, including podcasts, publications, and practical tools designed for clinicians and patients.

Tailored Education for Your Community

Join your regional community network, where education is tailored to meet local needs. Collaborate with peers from local and regional communities, share knowledge, and drive impactful changes together.

Explore Our Events

Explore Our Events

Featured MASLD/MASH Educators

play

Elizabeth Alqueza

PA-C

Elizabeth Alqueza, PA-C is a board certified Physician Associate at Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts. She graduated from the University of Florida in 2004 with a Master of Physician Assistant Studies degree and subsequently completed the AASLD NP/PA Clinical Hepatology Fellowship. Elizabeth has worked in a variety of inpatient and outpatient settings with a strong commitment to patient care. Currently working at BIDMC Liver Center, Elizabeth has 5 years of dedicated experience in Hepatology. Her practice focuses primarily on steatotic liver disease, including Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH). Elizabeth is an active member of Gastroenterology and Hepatology Advanced Practice Providers.

play

Michelle Barnett

PA-C, MPAS, DFAAPA

Michelle Barnett is a highly experienced physician assistant specializing in patient-focused and evidence-based hepatology at Peak Gastroenterology Associates in Colorado Springs, Colorado. The most rewarding part of her position includes educating patients and collaborating with other GI advanced practice providers to enhance care for the growing MASLD/MASH population. She is now a subinvestigtor for hepatology clinical trials with Peak in Colorado Springs. With over 30 years in the GI and liver communities, she has held leadership roles, including serving as President of the Colorado Academy of Physician Assistants (CAPA) and receiving CAPA's Physician Assistant of the Year award. She is a national speaker and has given lectures for the AAPA, GHAPP and AANP. A graduate of Wichita State University and the University of Nebraska, Michelle has been recognized with the DFAAPA distinction and honors such as the Crohn’s and Colitis Foundation's IBD internship and the International Foundation for Gastrointestinal Disorders Ally Award. Passionate about holistic care, she incorporates lifestyle strategies like nutrition, yoga, and meditation into her practice. Outside of work, Michelle enjoys hiking, travel, musical theater, and supporting her favorite Colorado sports teams.

play

Sherona Bau

NP

Sherona Bau graduated from University of California, Los Angeles in 2008, with Master of Science in Nursing dual program specialized in Acute Care Nurse Practitioner and Clinical Nurse Specialist. In 2010, she has joined UCLA Pfleger Liver Institute and Asian Liver Cancer Center working as an outpatient Nurse Practitioner specializing in liver diseases including viral hepatitis, hepatobiliary diseases, alcohol related liver diseases, Metabolic Dysfunction-Associated Steatotic Liver Disease/Steatohepatitis, autoimmune liver diseases, and hepatocellular carcinoma. Since 2016, she has been a guest lecturer at UCLA School of Nursing for Master Entry Clinical Nurse (MECN) and MSN Adult/Gero Acute Care program. She is also a preceptor for Adult/Gero Acute Care Program. She participated in Hepatitis C Screening in the Community Churches to promote awareness of hepatitis C and the importance of treatment of hepatitis C. She also participates in Patient Symposium at UCLA to give a lecture to update care of the liver transplant patients. She is also a faculty of Gastroenterology Hepatology Advanced Practice Provider (GHAPP) since 2018 and a speaker for both GHAPP National meeting and Regional GHAPP in Los Angeles. Since 2013, she has published total 14 research papers and case report including the most recent three are Recommendations for the Management of MASH by Advanced Practice Providers in the US, Clinicians and Patients Confront Practical Issues in Wilson Disease, and Overview of chronic Hepatitis B management.

MASLD/MASH Learning Center

Latest News & Blogs

Predictors of fibrosis, clinical events and mortality in MASLD: Data from the Global-MASLD study

November 2025

CONCLUSIONS: In this large global biopsy-based MASLD cohort, advanced fibrosis was highly prevalent and strongly linked to T2D. Both histologic fibrosis and NITs were independent predictors of mortality and clinical outcomes, underscoring the prognostic value of fibrosis assessment with non-invasive tests.

Read More arrow

Development and validation of a non-invasive score for at-risk metabolic dysfunction-associated steatohepatitis in individuals with obesity undergoing bariatric surgery

November 2025

CONCLUSION: -The FMO is an accurate and cost-effective non-invasive score for at-risk MASH identification in populations with obesity.

Read More arrow

S100A6 Regulated by PATZ1 Promotes Liver Fibrosis by Activating Hepatic Stellate Cells

November 2025

CONCLUSION: S100A6 acted as a downstream target of PATZ1 during HSC activation, and PATZ1 could inhibit HSCs activation through suppression the expression of S100A6. PATZ1/S100A6 offered a potential therapeutic target for the therapy of liver fibrosis.

Read More arrow

Current Update on Nomenclature, Diagnosis, and Management of Metabolic Dysfunction-associated Steatotic Liver Disease: Radiologists' Perspective

November 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the new name for nonalcoholic fatty liver disease (NAFLD). MASLD continues to be a significant global health care problem, commensurate with the increased prevalence of obesity and metabolic syndrome. The study of MASLD has intensified over the past 5 years, with major breakthroughs in understanding the pathogenesis and natural history. The American Association for the Study of Liver Diseases (AASLD) published practice guidance...

Read More arrow

Impact of Obesity and MASH on Zonal Hepatocellular Statin Exposure: Pharmacodynamic Insights From a Permeability-Limited Multicompartment Liver Model

November 2025

Statins are frequently prescribed for hyperlipidemia, a common comorbidity in patients with obesity and/or metabolic dysfunction-associated steatohepatitis (MASH). However, limited knowledge exists on how MASH may alter statin disposition within hepatocytes where the statin target, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, is located. This study used a physiologically based pharmacokinetic (PBPK)/permeability-limited multicompartment liver (PerMCL) framework, incorporating zonal...

Read More arrow

Dietary Interventions in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review of Evidence, Mechanisms, and Translational Challenges

November 2025

Background/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) is rapidly attracting growing concern around the world. While there has been progress in the development of pharmacologic treatments, lifestyle and dietary interventions remain as the first-line approach for management. This scoping review aimed to identify dietary strategies for managing MASLD and to highlight current research gaps and challenges. Methods: A systematic search of PubMed and Science Direct was...

Read More arrow

Hepatic Zonation in MASLD: Old Question, New Challenge in the Era of Spatial Omics

November 2025

Hepatic zonation reflects the concept that hepatocytes and nonparenchymal cells (NPCs) perform distinct metabolic functions, depending on their spatial localization along the porto-central axis. The maintenance of this fine-tuned organization is essential for liver homeostasis, and its disruption may contribute to liver diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD). Fat overload perturbs zonal gene signatures, lipid handling and oxygen/metabolite gradients...

Read More arrow

Metabolic dysfunction-associated steatotic liver disease and colorectal neoplasms risk: a global propensity score-matched retrospective cohort study

November 2025

CONCLUSIONS: MASLD and MASH are independent risk factors for CRC and BCN, irrespective of metabolic comorbidities. Fibrosis/cirrhosis does not significantly influence CRC risk. These findings support the need to revisit CRC screening guidelines for patients with MASLD/MASH. Further prospective studies are warranted to explore underlying mechanisms and evaluate preventative interventions.

Read More arrow

Reimagining Justice and Responsibility: A Critical Analysis of Differential Standards for Patients with Alcohol-Associated Liver Disease or Metabolic Dysfunction-Associated Steatohepatitis

November 2025

The demand for liver transplantation compounds the challenges of achieving justice. Scarcity raises questions about how candidate review committees determine which patients are suitable for transplantation, particularly for "perceived patient-induced diseases" (PPIDs). PPIDs are conditions arising partly from behaviors considered to be within the patient's control. We explore ethical issues in using different candidate review committee standards for PPIDs, comparing alcohol-associated liver...

Read More arrow

Sex disparities in liver transplantation for hepatocellular carcinoma: long-term outcomes and recurrence predictors

November 2025

CONCLUSIONS: Recipient sex does not impact long-term survival or HCC recurrence after LT. However, sex-specific predictors of HCC recurrence were identified: AFP score >2 and prior hepatectomy in females, and these plus diabetes mellitus and older age in males. Furthermore, female recipients presented with a significantly lower incidence of alcohol-associated cirrhosis as the underlying cause of HCC.

Read More arrow

METTLING in the pathogenesis of metabolic dysfunction-associated steatotic liver disease

November 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) progresses through distinct stages from hepatic lipid deposition or steatosis to metabolic dysfunction-associated steatohepatitis (MASH), and ultimately to cirrhosis or hepatocellular carcinoma (HCC). The pathogenesis of MASLD is dynamically regulated by epigenetic remodeling, among which the methyltransferase-like (METTL) family acts as a master regulator, coordinating multi-tiered pathological processes including modulating lipid...

Read More arrow

Metabolic Dysfunction-Associated Steatotic Liver Disease in Adults: A Review

November 2025

CONCLUSIONS: A highly prevalent condition among adults worldwide, MASLD is associated with liver-related complications, hepatocellular carcinoma, cardiovascular disease, and certain extrahepatic cancers. First-line treatment includes behavioral modifications, including a weight-reducing diet, physical exercise, and avoidance of alcohol. Resmetirom and semaglutide are conditionally FDA-approved medications for the treatment of adults with MASH and moderate to advanced fibrosis.

Read More arrow

Transferrin combined with alanine aminotransferase and body mass index improves non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis

November 2025

CONCLUSION: Our study highlights that a simple, cost-effective panel of routinely available biomarkers (BMI, ALT, and Tf) can effectively stratify MASLD progression, offering a practical alternative to invasive diagnostics. This approach enhances early MASH detection, facilitating timely clinical intervention.

Read More arrow

Large Language Models can Identify the Presence of MASH and Extract VCTE Measurements from Unstructured Documentation

November 2025

CONCLUSIONS: LLMs can extract MASH presence and VCTE parameters from documentation with high accuracy and low cost. When incorporated into survival analyses, LLM-extracted variables are associated with important clinical outcomes. Given the growing availability of LLMs, liver diseases researchers should incorporate these methods to facilitate real-world studies.

Read More arrow

Tregs With High CD29 Expression Promote Cell Adhesion and Contribute to the Malignant Transformation of MASLD

November 2025

CONCLUSIONS: Tregs promote cell adhesion through CD29 upregulation, inducing the malignant transformation of MASLD. Targeting CD29 may offer a potential strategy for preventing HCC in patients with MASH.

Read More arrow

Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance

November 2025

This practice recommendation serves as an update to the 2023 AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease (NAFLD), now known as Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (3) and provides implementable guidance on patient selection for treatment, consideration of comorbidities, and monitoring of treatment safety and efficacy of semaglutide. FDA-indication and Practice Recommendation: The Wegovy® formulation, whose...

Read More arrow

Primary Human Tissue Models for Metabolic Dysfunction-Associated Liver Disease - toward Streamlining Drug Discovery with Patient-Derived Assays

November 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form metabolic dysfunction-associated steatohepatitis (MASH) are prevalent chronic liver diseases that are closely linked to metabolic syndrome, type 2 diabetes, and cardiovascular complications. Despite their rising incidence and growing socioeconomic burden, effective therapies remain limited. Traditional preclinical models often fail to replicate the complexity of human MASLD, particularly in capturing the...

Read More arrow

Cost-Effectiveness of MASH Diagnosis and Management Approaches Among Those With Type 2 Diabetes

November 2025

CONCLUSION AND RELEVANCE: In this economic evaluation, screening followed by ILIs was found to be a cost-effective management approach for MASH and liver fibrosis among people living with T2D in all countries. Screening followed by pharmacological treatment was cost-effective in most countries. These results can inform health policy decision-making and further the development of WHO recommended interventions to address NCDs.

Read More arrow

Cost of Metabolic Dysfunction-Associated Steatotic Liver Disease Screening Among All People Living With Diabetes in Six Countries

November 2025

CONCLUSIONS: This study provides valuable guidance for policymakers and healthcare managers to integrate liver fibrosis screening strategies for people living with diabetes into national health budgets.

Read More arrow

Loss of LCAT Function Aggravates Metabolic Associated Steatohepatitis (MASH) in Golden Syrian Hamster

November 2025

Lecithin cholesterol acyltransferase (LCAT) plays a pivotal role in acyl-esterifying cholesterol intravascularly, but its function in metabolic dysfunction-associated steatotic liver disease (MASLD) or steatohepatitis (MASH) has remained uncertain both in murine models and humans for decades, which is largely attributable to the distinct differences in cholesterol metabolism between mice and humans. Previously, we created a novel golden Syrian hamster model deficient in LCAT activity. Herein, we...

Read More arrow